Abstract | OBJECTIVE: METHODS: In the present natural history-controlled study, 36 patients with SBMA treated with leuprorelin acetate for up to 84 months ( leuprorelin acetate-treated group; LT group) and 29 patients with SBMA with no specific treatment (non-treated group; NT group) were analysed. Disease progression was evaluated by longitudinal quantitative assessment of motor functioning using the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), and the modified Norris score. In addition, we selected two major clinical endpoint events, namely the occurrence of pneumonia requiring hospitalisation and death, to evaluate disease prognosis following long-term leuprorelin acetate treatment. RESULTS: In our analysis of the longitudinal disease progression using the random slope model, we observed a significant difference in the ALSFRS-R total score, the Limb Norris Score, and the Norris Bulbar Score (p=0.005, 0.026 and 0.020, respectively), with the LT group exhibiting a slower per-12-months decline compared with the NT group. As for the event analysis, the prognosis of the LT group was better in comparison to the NT group as for the event-free survival period (p=0.021). CONCLUSION: Long-term treatment with leuprorelin acetate appears to delay the functional decline and suppress the incidence of pneumonia and death in subjects with SBMA.
|
Authors | Atsushi Hashizume, Masahisa Katsuno, Keisuke Suzuki, Akihiro Hirakawa, Yasuhiro Hijikata, Shinichiro Yamada, Tomonori Inagaki, Haruhiko Banno, Gen Sobue |
Journal | Journal of neurology, neurosurgery, and psychiatry
(J Neurol Neurosurg Psychiatry)
Vol. 88
Issue 12
Pg. 1026-1032
(12 2017)
ISSN: 1468-330X [Electronic] England |
PMID | 28780536
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. |
Chemical References |
- Antineoplastic Agents, Hormonal
- Leuprolide
|
Topics |
- Adult
- Aged
- Antineoplastic Agents, Hormonal
(adverse effects, therapeutic use)
- Disease Progression
- Disease-Free Survival
- Endpoint Determination
- Female
- Humans
- Kaplan-Meier Estimate
- Leuprolide
(adverse effects, therapeutic use)
- Long-Term Care
- Male
- Middle Aged
- Muscular Atrophy, Spinal
(complications, drug therapy, genetics)
- Pneumonia
(complications, prevention & control)
- Prognosis
|